Vanguard Group Inc Oyster Point Pharma, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$7.95 - $11.68 $3.29 Million - $4.83 Million	-413,595 Reduced 96.84%	13,500 $150,000
Q3 2022 Nov 14, 2022	SELL	$4.41 - $8.38 $1.06 Million - $2.01 Million	-239,620 Reduced 35.94%	427,095 $2.4 Million
Q2 2022 Aug 12, 2022	SELL	$3.6 - $11.2 $3,412 - $10,617	-948 Reduced 0.14%	666,715 $2.89 Million
Q1 2022 May 13, 2022	BUY	$8.58 - $17.65 $47,104 - $96,898	5,490 Added 0.83%	667,663 $7.77 Million
Q4 2021 Feb 14, 2022	BUY	$10.17 - $18.96 $365,164 - $680,777	35,906 Added 5.73%	662,173 $12.1 Million
Q3 2021 Nov 12, 2021	BUY	$11.67 - $18.07 $52,176 - $80,790	4,471 Added 0.72%	626,267 $7.42 Million
Q2 2021 Aug 13, 2021	BUY	$16.25 - $21.51 $10.1 Million - $13.4 Million	621,796 New	621,796 $10.7 Million

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.